Polyphor provides update on the Phase III FORTRESS study of balixafortide in patients with advanced

Polyphor AG / Key word(s): Study results28-Jun-2021 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Allschwil, Switzerland, June 28, 2021Polyphor provides update on the Phase III FORTRESS study of balixafortide in patients...

Related Keywords

Allschwil ,Switzerland General ,Switzerland ,Swiss ,Hernan Levett ,Bernhard Schmid ,Guillaume Van Renterghem ,Polyphor Ltd ,Swiss Exchange ,Outer Membrane Protein Targeting Antibiotics ,சுவிட்சர்லாந்து ,சுவிஸ் ,ஹெர்னான் லெவெட் ,பெர்ன்ஹார்ட் ஸ்கிமிட் ,சுவிஸ் பரிமாற்றம் ,